STOCK TITAN

CRVO Form 3 — Officer Matthew Winton Reports Zero Holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

CervoMed Inc. (CRVO) filed an initial Form 3 reporting that Matthew Winton, identified as an officer (Chief Commercial and Business), does not beneficially own any securities of the company as of the event date 10/06/2025. The filing lists Winton's business address in Boston and is signed by the reporting person. No derivative or non-derivative holdings are disclosed.

Positive

  • None.

Negative

  • Officer Matthew Winton reported no beneficial ownership of CRVO shares
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Winton Matthew

(Last) (First) (Middle)
C/O CERVOMED INC.
20 PARK PLAZA, SUITE 424

(Street)
BOSTON MA 02116

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/06/2025
3. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial and Business
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Matthew Winton 10/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the CRVO Form 3 filed by Matthew Winton disclose?

It disclosed that Matthew Winton, an officer, does not beneficially own any CervoMed (CRVO) securities as of the event date 10/06/2025.

What role does the reporting person hold at CervoMed (CRVO)?

He is identified as an officer with the title Chief Commercial and Business.

Does the Form 3 list any derivative securities for CRVO owned by the reporting person?

No. The filing states that no securities are beneficially owned, and no derivative holdings are reported.

Was the Form 3 filed jointly or by a single reporting person?

The form was filed by one reporting person (single filer).

What address is listed for the reporting person on the Form 3?

The address given is 20 Park Plaza, Suite 424, Boston, MA 02116.
CervoMed

NASDAQ:CRVO

CRVO Rankings

CRVO Latest News

CRVO Latest SEC Filings

CRVO Stock Data

60.88M
6.28M
31.4%
23.56%
3.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON